{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00659620",
      "OrgStudyIdInfo": {
        "OrgStudyId": "fuzhough0712"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "fuzhough0712"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Organ Transplant Institute, China",
        "OrgClass": "OTHER_GOV"
      },
      "BriefTitle": "Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy",
      "OfficialTitle": "Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2008",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2008"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2008",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2010",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 14, 2008",
      "StudyFirstSubmitQCDate": "April 14, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 16, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "April 14, 2008",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 16, 2008",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "FUZHOU GENERAL HOSPITAL",
        "ResponsiblePartyOldOrganization": "FUZHOU GENERAL HOSPITAL"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Fuzhou General Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Mesenchymal Stem Cell (MSC) have been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.",
      "DetailedDescription": "Kidney transplantation is a common procedure in hospitals, but organ rejection and chronic nephrotoxicity are potential problems for the patient. Approximately ninety percent of the protocol biopsies of renal allografts, performed at 18 months post transplantation, show histological lesions of chronic calcineurin nephrotoxicity. Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties. Some patient in this study will also receive two infusions of expanded MSC. This study will evaluate the safety and effectiveness of MSC infusions in patients .\n\nThis study will last 2 years. Participants will be randomly assigned to receive either the full immunosuppressive therapy and MSC infusions (Group 1) or immunosuppressive therapy alone (Group 2). Patients will undergo MSC infusions at the start of the study on Day 0. One year post- infusions, patients will be evaluated. At Months 12 participants will undergo kidney biopsies. Blood collection will occur at regular intervals, Serum creatinine and the estimated creatinine clearance will be monthly recorded. The transplanted kidney function will be evaluated."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Kidney Transplant",
          "Chronic Allograft Nephropathy"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Kidney Transplant",
          "Chronic Allograft Nephropathy",
          "Mesenchymal Stem Cell infusion"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "transplantation of mesenchymal stem cell",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: mesenchymal stem cell"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "mesenchymal stem cell",
            "InterventionDescription": "transplantation of mesenchymal stem cell",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "MMF FK506"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Creatinine and creatinine clearance rate",
            "PrimaryOutcomeTimeFrame": "5"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Patient and graft survival [ Time Frame: At 1 years post-transplant ].",
            "SecondaryOutcomeTimeFrame": "5"
          },
          {
            "SecondaryOutcomeMeasure": "The proportion of renal biopsy after 12 months",
            "SecondaryOutcomeTimeFrame": "2"
          },
          {
            "SecondaryOutcomeMeasure": "The incidence of infectious complications",
            "SecondaryOutcomeTimeFrame": "5"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of adverse events associated with MSC and immunosuppression",
            "SecondaryOutcomeTimeFrame": "5"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nRecipients of a renal allograft, Male and female patients age 18 to 60 years of age.\nAbility to provide written informed consent.\nThe serum creatinine form 176umol/L(2mg/ml) to 440umol/L(5mg/ml)\nRenal biopsy Criteria: chronic allograft nephropathy (Banff I-II).\nImmunosuppressant:CNI and MMF and Sirolimus\nWritten informed consent, compliant with local regulations.\n\nExclusion Criteria:\n\nRecipients with leucopenia (WBC < 3000/mm³), thrombocytopenia (Thr < 100.000/mm³),or hyperlipidemia (Tot Chol > 300 mg/dl or Triglycerides > 300 mg/dl).\nRecipients of multiple organs.\nPregnant women.\nPrevious history of malignancy\nActive infection including hepatitis B, hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB.\nEvidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months.\nInadequate compliance to treatment.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jianming Tan T Jianming, Professor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "008613375918000",
            "CentralContactEMail": "DOCTORTJM@YAHOO.COM"
          },
          {
            "CentralContactName": "Junqi Guo G Junqi, vicProfessor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "008613960941458",
            "CentralContactEMail": "guojunq2002@yahoo.com.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jianming Tan T Jianming, professor",
            "OverallOfficialAffiliation": "Fuzhou General Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Fuzhou General Hospital",
            "LocationCity": "Fuzhou",
            "LocationState": "Fujian",
            "LocationZip": "350025",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jianming Tan T Jianming, professor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "008613375918000",
                  "LocationContactEMail": "doctortjm@YAHOO.COM"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007674",
            "ConditionMeshTerm": "Kidney Diseases"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafAsFound": "Nephropathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M18102",
            "InterventionBrowseLeafName": "Tacrolimus",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}